Search

Displaying results 7411 - 7420 of 8171 in total
  1. Drug

    Proxalutamide

    go.drugbank.com/drugs/DB16065
    Investigational

    Proxalutamide is under investigation in clinical trial NCT03899467 (The Safety and Tolerability of Proxalutamide (GT0918) in Subjects With Metastatic Castrate Resistant Prostate Cancer).

  2. Drug

    CTCE-0214

    go.drugbank.com/drugs/DB05934
    Experimental

    CTCE-0214 is a stable peptide agonist of stromal cell-derived factor-1 (SDF-1), a key signaling molecule in the proliferation, homing, engraftment and expansion of hematopoietic stem cells and white blood cells.

  3. Drug

    Iclaprim

    go.drugbank.com/drugs/DB06358
    Investigational

  4. Drug

    Spaglumic acid

    go.drugbank.com/drugs/DB08835
    Investigational

    Spaglumic acid is the β-aspartyl isoform of N-Acetyl-l-aspartylglutamate (isospaglumic Acid is N-(N-Acetyl-l-α-aspartyl)-l-glutamic acid). In eye drops, spaglumic acid is either a magnesium or sodium salt of N-Acetyl-l-aspartylglutamate....

  5. Drug

    Flupirtine

    go.drugbank.com/drugs/DB06623
    Investigational

    Flupirtine is a pyridine derivative that is in clinical use as a nonopioid analgesic. It was approved for the treatment of pain in 1984 in Europe. It is not approved for use in the U.S. or Canada, but is currently in phase II trials for ...

  6. Drug

    Rizatriptan

    go.drugbank.com/drugs/DB00953
    ApprovedInvestigational

    Rizatriptan is a second-generation triptan and a selective 5-HT1B and 5-HT1D receptor agonist. Used in the treatment of migraines, rizatriptan was first approved in the US in 1998. Rizatriptan is available in oral tablets, orally disinte...

    Categories: Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 Enzyme InhibitorsProducts: Van-rizatriptan, Van-rizatriptan ODT
  7. Drug

    Chromous sulfate

    go.drugbank.com/drugs/DB14530
    Approved

  8. Drug

    CRx-139

    go.drugbank.com/drugs/DB05744
    Experimental

    CRx-139 is an oral synergistic combination drug candidates with novel mechanisms of action targeting multiple biological pathways simultaneously.

  9. Drug

    Muraglitazar

    go.drugbank.com/drugs/DB06510
    Investigational

    In addition to improvements in blood glucose and hemoglobin A1c (HbA1c), muraglitazar treatment is associated with a substantial reduction in triglycerides (TGs), an increase in HDL-C, and a modest decrease

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Substrates
  10. Drug

    LX1031

    go.drugbank.com/drugs/DB05199
    Investigational

    LX1031 is an orally-dosed drug candidate for irritable bowel syndrome and other gastrointestinal disorders.